Chapter 207 - 205: TRP Reagent for Phase 1 Clinical Trial

Chapter 207: Chapter 205: TRP Reagent for Phase 1 Clinical Trial

"The Sakurans are sycophantic to the strong, cruel to the weak, inherently greedy, utterly shameless, and exceptionally ruthless!"

"The Sakurans are extremely twisted and treacherous. They are simply disgusting!"

She had finally seen through the true nature of the Sakurans. She had been thoroughly deceived, played for an absolute fool, and had slandered Veridia, the motherland that had nurtured her for so long.

But as she looked hopefully at the interrogators before her, only to see the coldness in their eyes, she instantly understood. There was no going back. Everything was ruined.

Rian Sinclair watched the female streamer’s back in silence, not saying another word. The people around her looked at her excitedly. Rian greeted them briefly before leaving the crowd.

She had indeed come here today with a premeditated plan. The woman in the video she had scrolled past yesterday was her; the one trending online was her. She could have done far more meaningful street interviews, yet she had chosen to rely on stepping on others—elevating one by tearing down another—just to gain attention. Her behavior was extreme, but more importantly, she never should have belittled Veridia. Today’s events made Rian realize even more profoundly that, for a nation, technological development was of paramount urgency.

Rian returned to the laboratory. She had no other pressing matters, save for the news Donovan Sinclair had received: the higher-ups had passed the regulatory review for the TRP Reagent.

What did this mean? It meant the TRP Reagent could be used clinically. It could soon be tested on humans and, eventually, help countless more patients.

Upon arriving at the lab and seeing Donovan, Rian asked, "How is it? Have the participants for the Phase I clinical trials been found?"

Rian knew that, generally, any medication intended for human use had to undergo various animal tests. Only after confirming there were no issues could an application be submitted to the higher-ups. It required approval from the relevant competent authorities and review by the ethics committee. Only then could they recruit healthy volunteers who had passed medical examinations and met the criteria for testing. The laboratory would provide these volunteers with cash subsidies, ensuring they wouldn’t face severe harm.

However, adverse reactions to the medication were inevitable, though the impact would be minimal. Furthermore, the entire process had to be conducted under the supervision of doctors who would meticulously record all the data. It wasn’t suitable for just anyone; the criteria were extremely strict, so the execution of the trial had to be taken very seriously.

This was the reality of medical trials. They required rigorous gatekeeping. It was a matter of being responsible for everyone involved. Even if this became public knowledge, it wouldn’t cause much of a stir because they would clearly communicate everything they were doing to the participants, without an ounce of concealment. The initial nutrition allowances and subsequent subsidies would all be distributed according to regulations. Moreover, these drugs had been subjected to strict and repeated testing to ensure they wouldn’t endanger human health before trials even began.

As for whether there would be any irreversible reactions in the human body later on, Rian still didn’t know. During the experimental phase, she had tested it on various small animals, particularly those with genes similar to humans, but she hadn’t found any irreversible variables.

"Miss," Donovan began. "The higher-ups have agreed. They deem the TRP Reagent viable, and we are currently looking for Phase I clinical participants."

Rian nodded. The next step was to begin another set of trials.

"Arrange for the medical staff to come over immediately. We need experts in this field. Increase the compensation for the Phase I clinical trial by five percent from the original base.

"As soon as Phase I concludes, arrange for Phase II immediately.

"Everyone needs to be meticulous. What I need is for the TRP Reagent to be fully launched later. I don’t want to waste extra time on futile efforts."

"Understood, Miss. The Phase I participants are being arranged right now, and medical staff are being transferred from various companies. They are expected to arrive in an hour.

"The healthy volunteers for Phase I will arrive in batches in two hours."

Rian nodded, and Donovan immediately went to make the arrangements. Returning to the laboratory, Rian looked around at the familiar equipment and couldn’t help but say aloud, "Thank goodness I’m not here to lose hair this time."

It couldn’t be helped. Her last experiment was something basically impossible for one person to complete. However, with the enhancement of her points, Rian’s brain could no longer be measured by the standards of a Blue Star Human. Still, that experiment had likely cost her far too many brain cells. She decided that for future experiments, she needed to recruit people with an abundance of brain cells to help out. That way, she could delegate some of the minor tasks and wouldn’t have to handle every experiment herself.

Rian prepared the necessary items in the lab. Not knowing how many trial participants there would be, she readied fifty doses of the reagent.

But when she saw the arriving Phase I clinical participants, she was shocked. She had no idea so many people would be willing to come. After all, even as the lead researcher, she didn’t know what harm the reagent might inflict on the human body. It was an unknown. Therefore, recruiting participants for Phase I usually took a very long time.

But the words of the people there left Rian in stunned silence.

"I’m very healthy, and I want to be a Phase I trial participant," one man said. "I’m more than willing because my wife has terminal breast cancer. I love her very much, and she loves me. We have a healthy baby, and our family is even willing to sell our house and car to treat her."

"My son was diagnosed with terminal lung cancer," another shared. "I don’t want to bury my own child. My son is wonderful; he loves me and his mother deeply. Every time we hear about this kind of trial, my wife and I sign up just to save him. I want him to get better."

"My son is only three years old and has cancer," a third added. "He hasn’t even had the chance to properly see this world. His father died of cancer, and I can’t lose him too. I volunteer to be a clinical trial participant. I want to save him. I hope he can grow up healthy. Even if it means trading my life for his, I am entirely willing."

"I just hope my family will be okay. I can’t bear to see him suffer," another echoed.

"Let’s hurry up and start the trial. I volunteer to participate."

Rian listened to their words in silence. They all had family members suffering from cancer. It was precisely for this reason that they were willing to come. Even if the chances were slim, as long as there was a glimmer of hope, they would flock to it.

Donovan also remained silent. The surrounding medical staff had red-rimmed eyes. As healthcare professionals, they understood the agony of cancer patients better than anyone. They also acutely understood the pain of the patients’ families—the profound helplessness of spending a lifetime’s savings to treat their loved ones, yet still being unable to save them despite squandering everything they had.

Rian simply glanced at the people around her. There was a light in all their eyes—a spark that hadn’t been worn away by failure after failure. They were constantly trying to save the people they loved, and the people who loved them.

"Phase I of the clinical trials begins now," Rian announced. "Please line up in an orderly manner and follow the medical staff.

"I will do everything in my power to take care of you all. Thank you so much for participating in this clinical trial."

Rian watched as everyone followed the medical staff away. Donovan stepped forward. "There are one hundred and fifty people for Phase I, and patients have also registered for Phase II."

Rian nodded, then turned to leave. She hadn’t prepared nearly enough doses of the reagent. She needed to prepare more. She could understand their emotions. She fervently hoped that the reagent she developed could be safely used on patients—she hoped, more than anything, to save them.